Danielle Ternyila | Authors


Camrelizumab Combo Elicits Encouraging Efficacy in Second-Line Esophageal Squamous Cell Carcinoma

January 15, 2021

Camrelizumab in combination with apatinib demonstrated encouraging clinical efficacy as a second-line treatment of patients with esophageal squamous cell carcinoma and demonstrated acceptable safety in a single-arm, open-label phase 2 clinical trial.

Analysis Determines Potential Feasibility of PSMA PET Imaging for Metastatic Thyroid Cancer

January 14, 2021

Gallium-68 prostate-specific membrane antigen PET imaging demonstrated the ability to detect metastatic thyroid cancer but resulted in a lower detection rate compared with 2-[18F]FDG PET for thyroid cancer lesion visualization.